Sema4 Signs a Definitive Agreement to Acquire GeneDx for ~$623M
Shots:
- Sema4 will acquire GeneDx for a total consideration of ~$623M including $150M up front in cash, 80.0M shares in Sema4's common stock (~$473M as total upfront), ~$150M revenue-based milestones for a next 2 yrs. The combined company is expected to provide $350M in pro forma 2022 revenue
- Sema4 also entered into agreements for a $200M private placement in Class A common stock at $4.00/share from Pfizer & institutional investors. The transaction is expected to close in Q2’22,
- The acquisition strengthens Sema4’s AI-driven genomic & clinical data intelligence platform & add GeneDx’s database of clinical exomes & annotated phenotypes to Sema4’s platform to enable precision medicine to patients
Ref: Sem4 | Image: HIT Consultant
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com